Pharmacogenetic testing: Utility in drug development and in routine clinical practise;Tests pharmacogénétiques: Leur place en pratique médicale courante et dans le développement des médicaments

Bulletin de l'Academie Nationale de Medecine

Volumn 190, Issue 1, 2006, Pages 25-36

  Jaillon, Patrice ^a   Giroud, Jean Paul ^b   Boulu, Roger ^b   Larcan, Alain ^b   Delaveau, Pierre ^b   Rondot, Pierre ^b  

^a SORBONNE UNIVERSITÉ   (France)

^b NONE

Author keywords

Cytochrome P 450 enzyme system; Metabolism; Pharmacogenetics

Indexed keywords

EID: 33745782528     PISSN: 00014079     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0001-4079(19)33351-5     Document Type: Review

References (14)

1. WILKINSON G.R. - Drug metabolism and variability among patients in drug response. N Eng. J. Med, 2005, 352, 11-2221.
2. BODIN L., VERSTUYFT C., TREOOUET D.A., ROBERT A., DUBERT L., FUNCK-BRENTANO C. et al - Cytochrome P450 2C9 (CYP 2C9) and vitamin K epoxyde reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood, 2005, 106, 135-140.
3. QUTEINEH L., VERSTUYFT C., DESCOT C., DUBERT L., ROBERT A., JAILLON P. et al. - Vitamin K epoxyde reductase (VKORC) genetic polymorphism is associated to oral anticoagulant overdose. Thromb. Haemost., 2005, 94, 690-691.
4. MEYER U.A - Pharmacogenetics and adverse drug reactions. Lancet, 2000, 356, 1667-1671.
5. LAZAROU I, POMERANZ B.H., COREY P.N. - Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA, 1998, 279, 1200-1205.
6. IMBS J.L., POUYANNE P., HARAMBURU F., WELSCH M., DECKER N., BLAYAC J.P. et al. - latrogénie médicamenteuse: estimation de sa prévalence dans les hôpitaux publics français. Therapie, 1999, 54, 21-27.
7. VISSER L.E., VAN SHAIK R., VAN VLIET M., TRIENEKENS P.H., DESMET P.A., VULTO A.G. et al. - Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal antiinflammatory drugs and coumarin anticoagulants. Clin. Pharmacol. Ther., 2005, 77, 479-485.
8. OZDEMIR V., SHEAR N.H., KALOU W. - What will be the role of pharmacogenetics in evaluating drug safety and minimising adverse effects? Drug Safety, 2001, 24, 75-85.
9. ROSES A.D. - Pharmacogenetics and drug development: the path to safer and more effective drugs Nature Rev. Genetics, 2004, 5, 645-656.
10. VOGEL C.L., FRANCO S.X. - Clinical experience with trastuzumab (herceptin). Breast J., 2003, 9, 452-462.
11. LESKO L., SALERNO R.A., SPEAR B.B., ANDERSON D., ANDERSON T., BRAZELL C. et al - Pharmacogenetics and pharmacogenomics in drug development and regulatory decision making report of the first FDA - PWG-PhRMA - DruSafe Workshop. J. Clin. Pharmacol., 2003, 43, 342-358.
12. LESKO L.J., WOOSCOCK J. - Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective. Nature Reviews, 2004, 3, 763-769.
13. SALERNO R.A., LESKO L.J. - Pharmacogenomic data: FDA voluntary and required submission guidance - Pharmacogenomics, 2004, 5, 503-505.
14. http://www.fda.gov/cder/guidance/5900dft.pdf - Data Guidance for industry: Pharmacogenomic Data Submission.